Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05378529 · ClinicalTrials.gov registry record · NA
A Cross-sectional Study of Lipoprotein(a) Levels in Patients With Documented History of Atherosclerotic Cardiovascular Disease (ASCVD)
A NA study of Atherosclerotic Cardiovascular Disease, sponsored by Amgen.
- Completed
- Registry status
- NA
- Development phase
- 39,480
- Enrollment target
- 20
- Study locations
NCT05378529 is a NA study of Atherosclerotic Cardiovascular Disease that has completed, run by Amgen. The registered enrollment target is 39,480 participants, above the 5,688-participant average among 21 other Atherosclerotic Cardiovascular Disease trials with a reported enrollment target (594% higher). The trial reports 20 study locations across 8 states.
The verdict
NCT05378529, a NA study of Atherosclerotic Cardiovascular Disease, has completed, sponsored by Amgen.
- COMPLETED
- Registry status
- NA
- Development phase
- 39,480 participants
- Enrollment target
- 20
- Study locations
Study Summary
The purpose of this study is to characterize the distribution of lipoprotein(a) (Lp(a)) levels among participants with a history of ASCVD as defined by their medical history and is 2-fold: * Evaluate the distribution of Lp(a) value in the overall participants with documented history of ASCVD * Evaluate the distribution of Lp(a) value in participants with documented history of ASCVD by demographics and regions
Conditions Studied
Interventions
- OTHER Lp(a) Screening
Study Locations (20)
California
- Care Access - Berkeley - Berkeley
- National Heart Institute - Beverly Hills
- NorCal Medical Research, Inc - Greenbrae
- America Clinical Trials - Tarzana
- Med Partners, Inc dba Premiere Medical Center, Inc - Toluca Lake
Florida
- Excel Medical Clinical Trials - Boca Raton
- Bay Area Cardiology - Brandon
- Clearwater Cardiovascular Consultants - Clearwater
- Cardiology Associates Research LLC - Daytona Beach
- The Cardiac and Vascular Institute Research - Gainesville
Alabama
- Ascension Saint Vincents Birmingham - Birmingham
- Grandview Medical Center Affinity Cardiovascular Specialists, LLC - Birmingham
- Heart Center Research LLC - Huntsville
- Mobile Heart Specialists PC - Mobile
Arizona
- Care Access - Mesa - Mesa
- Elite Clinical Studies LLC - Phoenix
Alaska
- Alaska Cardiovascular Research Foundation - Anchorage
Arkansas
- Arkansas Cardiology - Little Rock
Colorado
- UCHealth Memorial Central - Colorado Springs
Connecticut
- Cardiology Associates of Fairfield County PC - Stamford
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 39,480 participants |
| Start Date | 2022-04-19 |
| Est. Completion | 2023-12-30 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05378529
The ClinicalTrials.gov registry entry for NCT05378529 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 39,480 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 5,688-participant average among 21 other Atherosclerotic Cardiovascular Disease trials with a reported enrollment target (594% higher). The listed sponsor is Amgen, which has 558 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Atherosclerotic Cardiovascular Disease appearing as the primary indexed condition, and to 1 intervention - of which Lp(a) Screening is the first listed.
NCT05378529 reports 20 study locations spanning 8 distinct geographic areas - top geographies include California, Florida, Alabama.
Frequently Asked Questions
What is clinical trial NCT05378529 about?
NCT05378529 is a clinical study titled "A Cross-sectional Study of Lipoprotein(a) Levels in Patients With Documented History of Atherosclerotic Cardiovascular Disease (ASCVD)". The purpose of this study is to characterize the distribution of lipoprotein(a) (Lp(a)) levels among participants with a history of ASCVD as defined by their medical history and is 2-fold: * Evaluate the distribution of Lp(a) value in the overall participants with documented history of ASCVD * Eval...
What is the current status of trial NCT05378529?
This trial is currently completed. It is a NA study. The enrollment target is 39,480 participants. The study started on 2022-04-19. Estimated completion is 2023-12-30.
What conditions does trial NCT05378529 study?
This clinical trial studies the following conditions: Atherosclerotic Cardiovascular Disease.
What interventions are being tested in trial NCT05378529?
The interventions under investigation include: Lp(a) Screening (OTHER).
Who is sponsoring clinical trial NCT05378529?
This trial is sponsored by Amgen, which has 558 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05378529 being conducted?
This trial has 20 study locations across Alabama, Alaska, Arizona, Arkansas, California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Atherosclerotic Cardiovascular Disease
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Pragmatic INitiative for LDL-C Management by a CLinical Pharmacist-Led Team Among Atherosclerotic CardiovascUlar DisEase Patients
RECRUITING · NA
-
Polygenic Risk Score Implementation and Stratification for Managing Blood Pressure
RECRUITING · NA
-
The Young Heart Study
ACTIVE NOT RECRUITING · NA
-
Behavioral Economic Approaches to Increase Physical Activity Among Patients With Elevated Risk for Cardiovascular Disease
COMPLETED · NA
-
Recipe for Heart Health
COMPLETED · NA
-
Pilot Study to Evaluate the Effect of Nicotinamide Riboside on Immune Activation in Psoriasis
COMPLETED · NA
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.